YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
True Velocity, Inc./DE (NASDAQ:YDES) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
True Velocity, Inc./DE (NASDAQ:YDES) is now covered by analysts at
Weiss Ratings. They set a "sell (d+)" rating on the stock.
YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center